Table 4 HRs and 95% CIs for cancer-specific death according to MSI screening status and CIMP status in colorectal cancer patients with low, intermediate, and high total CD3 score

From: Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor

  

Total CD3 score

 

All cases

3–4

5–6

7–12

MSI screening status

 MSI

5-year cancer-specific survival

72%

51%

63%

87%

Univariate HR

1

1

1

1

Multivariate HRa

1

1

1

1

 MSS

5-year cancer-specific survival

57%

39%

54%

83%

Univariate HR

1.64 (0.93–2.87)

1.48 (0.46–4.78)

1.03 (0.45–2.34)

1.91 (0.55–6.65)

Multivariate HRa

1.16 (0.64–2.08)

0.78 (0.23–2.61)

1.02 (0.41–2.58)

2.64 (0.62–11.25)

CIMP status

 CIMP-0b

5-year cancer-specific survival

63%

48%

60%

84%

Univariate HR

1

1

1

1

Multivariate HRa

1

1

1

1

 CIMP-lowb

5-year cancer-specific survival

52%

29%

51%

88%

Univariate HR

1.46 (0.99–2.16)

2.11 (1.14–3.89)

1.23 (0.64–2.38)

0.77 (0.25–2.28)

Multivariate HRa

1.47 (0.98–2.20)

3.07 (1.53–6.15)

1.24 (0.60–2.55)

0.58 (0.17–1.92)

 CIMP-highb

5-year cancer-specific survival

64%

50%

53%

81%

Univariate HR

1.00 (0.57–1.76)

0.99 (0.33–2.93)

1.52 (0.63–3.66)

0.85 (0.25–2.76)

Multivariate HRa

1.09 (0.59–2.03)

1.34 (0.42–4.24)

0.99 (0.31–3.09)

0.48 (0.08–2.76)

  1. Abbreviations: CI, confidence interval; CIMP, CpG island methylator phenotype, according to an eight-gene panel; HR, hazard ratio, determined by Cox proportional hazard models; MSI, microsatellite instability; MSS, microsatellite stable.
  2. aAdjusted for sex, age, tumor site, tumor stage, and adjuvant chemotherapy.
  3. bCIMP-negative, 0 genes hypermethylated; CIMP-low, 1–5 genes hypermethylated; CIMP-high, 6–8 genes hypermethylated.
Back to article page